Publications

BibTex format

@article{Naqash:2021:10.21037/atm-20-6427,
author = {Naqash, AR and Kihn-Alarcon, AJ and Stavraka, C and Kerrigan, K and Vareki, SM and Pinato, DJ and Puri, S},
doi = {10.21037/atm-20-6427},
journal = {Annals of Translational Medicine},
pages = {1--11},
title = {The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer},
url = {http://dx.doi.org/10.21037/atm-20-6427},
volume = {9},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Immunotherapy has led to a paradigm shift in the treatment of several cancers. There have been significant efforts to identify biomarkers that can predict response and toxicities related to immune checkpoint inhibitor (ICPI) therapy. Despite these advances, it has been challenging to tease out why a subset of patients benefit more than others or why certain patients experience immune-related adverse events (irAEs). Although the immune-modulating properties of the human gut bacterial ecosystem are yet to be fully elucidated, there has been growing interest in evaluating the role of the gut microbiome in shaping the therapeutic response to cancer immunotherapy. Considerable research efforts are currently directed to utilizing metagenomic and metabolic profiling of stool microbiota in patients on ICPI-based therapies. Dysbiosis or loss of microbial diversity has been associated with a poor treatment response to ICPIs and worse survival outcomes in cancer patients. Emerging data have shown that certain bacterial strains, such as Faecalibacterium that confer sensitivity to ICPI, also have a higher propensity to increase the risk of irAEs. Additionally, the microbiome can modulate the local immune response at the intestinal interface and influence the trafficking of bacterial peptide primed T-cells distally, influencing the toxicity patterns to ICPI. Antibiotic or diet induced alterations in composition of the microbiome can also indirectly alter the production of certain bacterial metabolites such as deoxycholate and short chain fatty acids that can influence the anti-tumor tolerogenesis. Gaining sufficient understanding of the exact mechanisms underpinning the interplay between ICPI induced anti-tumor immunity and the immune modulatory role gut microbiome can be vital in identifying potential avenues of improving outcomes to cancer immunotherapy. In the current review, we have summarized and highlighted the key emerging data supporting the role of gut microbiome in regu
AU  - Naqash,AR
AU  - Kihn-Alarcon,AJ
AU  - Stavraka,C
AU  - Kerrigan,K
AU  - Vareki,SM
AU  - Pinato,DJ
AU  - Puri,S
DO  - 10.21037/atm-20-6427
EP  - 11
PY  - 2021///
SN  - 2305-5839
SP  - 1
TI  - The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
T2  - Annals of Translational Medicine
UR  - http://dx.doi.org/10.21037/atm-20-6427
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000671779000016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://atm.amegroups.com/article/view/63735/html
UR  - http://hdl.handle.net/10044/1/91631
VL  - 9
ER  -

Download

Dr. David James PINATO

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)